334 related articles for article (PubMed ID: 20944091)
1. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner K; Melton DW
Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
[TBL] [Abstract][Full Text] [Related]
2. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
Bergstralh DT; Sekelsky J
Trends Genet; 2008 Feb; 24(2):70-6. PubMed ID: 18192062
[TBL] [Abstract][Full Text] [Related]
3. Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair.
Rahn JJ; Adair GM; Nairn RS
Environ Mol Mutagen; 2010 Jul; 51(6):567-81. PubMed ID: 20658648
[TBL] [Abstract][Full Text] [Related]
4. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
McNeil EM; Melton DW
Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
[TBL] [Abstract][Full Text] [Related]
5. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
6. The ERCC1 and ERCC4 (XPF) genes and gene products.
Manandhar M; Boulware KS; Wood RD
Gene; 2015 Sep; 569(2):153-61. PubMed ID: 26074087
[TBL] [Abstract][Full Text] [Related]
7. Excision repair cross complementing-group 1: gene expression and platinum resistance.
Altaha R; Liang X; Yu JJ; Reed E
Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
[TBL] [Abstract][Full Text] [Related]
8. XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF.
Lehmann J; Seebode C; Smolorz S; Schubert S; Emmert S
Cell Mol Life Sci; 2017 Jun; 74(11):2081-2094. PubMed ID: 28130555
[TBL] [Abstract][Full Text] [Related]
9. Xeroderma pigmentosum and molecular cloning of DNA repair genes.
Boulikas T
Anticancer Res; 1996; 16(2):693-708. PubMed ID: 8687116
[TBL] [Abstract][Full Text] [Related]
10. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
12. Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.
Ahmad A; Enzlin JH; Bhagwat NR; Wijgers N; Raams A; Appledoorn E; Theil AF; J Hoeijmakers JH; Vermeulen W; J Jaspers NG; Schärer OD; Niedernhofer LJ
PLoS Genet; 2010 Mar; 6(3):e1000871. PubMed ID: 20221251
[TBL] [Abstract][Full Text] [Related]
13. Domain mapping of the DNA binding, endonuclease, and ERCC1 binding properties of the human DNA repair protein XPF.
McCutchen-Maloney SL; Giannecchini CA; Hwang MH; Thelen MP
Biochemistry; 1999 Jul; 38(29):9417-25. PubMed ID: 10413517
[TBL] [Abstract][Full Text] [Related]
14. ERCC1-XPF targeting to psoralen-DNA crosslinks depends on XPA and FANCD2.
Sabatella M; Pines A; Slyskova J; Vermeulen W; Lans H
Cell Mol Life Sci; 2020 May; 77(10):2005-2016. PubMed ID: 31392348
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
16. XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening.
Wu Y; Zacal NJ; Rainbow AJ; Zhu XD
DNA Repair (Amst); 2007 Feb; 6(2):157-66. PubMed ID: 17055345
[TBL] [Abstract][Full Text] [Related]
17. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair.
Tripsianes K; Folkers G; Ab E; Das D; Odijk H; Jaspers NG; Hoeijmakers JH; Kaptein R; Boelens R
Structure; 2005 Dec; 13(12):1849-58. PubMed ID: 16338413
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
19. Function and Interactions of ERCC1-XPF in DNA Damage Response.
Faridounnia M; Folkers GE; Boelens R
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563071
[TBL] [Abstract][Full Text] [Related]
20. Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms.
Wu Y; Mitchell TR; Zhu XD
Mech Ageing Dev; 2008 Oct; 129(10):602-10. PubMed ID: 18812185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
